MAP2K7 and non-small cell lung carcinoma: In another co-culture model of peripheral blood mononuclear cell (PBMC) and non-small-cell lung cancer (NSCLC) PDO, MEK-targeted drugs and immune checkpoint inhibitors have synergistic anti-tumor effects by increasing T cell reactivity [12].